Quick Search
Products c-Jun, Recombinant, Human
| Catalogue number: | C5815-02 |
| Size: | 2ug |
| Form: | Supplied as a lyophilized powder without additives. |
| Purity: | (same/more than) 95% (SDS-PAGE) |
| References: | 1. ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene 2006 Jul 3; 2. Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors. Mol Cell Biol 2006 Jul;26(14):5518-27 3. Loss of hepatic NF-{kappa}B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 2006 Jun 28; 4. Aldose Reductase-Deficient Mice Are Protected From Delayed Motor Ner ve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage. Diabetes 2006 Jul;55(7):1946-53 5. Homophilic interactions of the tetraspanin CD151 up-regulate motility and MMP-9 expression of human melanoma cells through adhesion-dependent c-jun activation signaling pathways. J Biol Chem 2006 Jun 23; 6. Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation. Circ Res 2006 Jun 22; |
Get the Best Promotions
